Lekhim established in Kyiv, Ukraine, initiating distribution activity (import and export operations).

Manufacturing unit Lekhim-Kharkiv established in Kharkiv, Ukraine.

Lekhim-Kharkiv launched suppositories production.

Lekhim acquired Technolog manufacturing plant in Uman, Ukraine.

Lekhim-Kharkiv commissioned a new solid dosage forms workshop.

Lekhim-Kharkiv launched production of sterile forms (small-volume liquids/aseptic filling line).

Consolidation of Lekhim, Lekhim-Kharkiv, and Technolog into the Lekhim Group of Pharmaceutical Companies.

Technolog completed a full-scale reconstruction of two solid dosage forms workshops.

Technolog obtained GMP certification.

Lekhim-Kharkiv commissioned a new warehouse complex.

Lekhim-Kharkiv obtained GMP certification.

Lekhim-Kharkiv launched a third production line for sterile small-volume liquids.

UAB Lekhim-Vilnius, export and import company, was established in Vilnius, Lithuania.

Technolog obtained European GMP certification.

Founded Lekhim-Obukhiv, the Group's third manufacturing unit; construction of the manufacturing facilities began in Obukhiv, Ukraine.

Technolog commissioned third workshop, a high-capacity state-of-the-art facility for non-sterile solid and liquid forms.

Lekhim commenced construction of the Group’s fourth manufacturing unit, located in Uzbekistan.

Technolog achieved WHO Prequalification (WHO PQ).

Lekhim became the sole official importer of the CoronaVac® COVID-19 vaccine (Sinovac Life Sciences) to Ukraine.

Lekhim commissioned a new state-of-the-art warehouse complex in Obukhiv.

Lekhim obtained a GDP Certificate.

Lekhim-Obukhiv obtained a manufacturing license and commenced industrial-scale production.

Lekhim-Kharkiv commissioned a new production workshop for pre-filled syringes.

Track & Trace system was implemented across all companies of Lekhim Group.

Commissioned a new 1,000 sq. m. R&D Center at Technolog focused on the development of solid and liquid forms.

Lekhim-Obukhiv commissioned full-cycle manufacturing operations.

Lekhim-Kharkiv became the first manufacturer in Ukraine to master industrial-scale suppository production technology.

Lekhim-Kharkiv was among the first in Ukraine to implement aseptic filling technology for sterile products.

Technolog improved the development of enzyme-based products with gastro-resistant coating.

Technolog implemented micro-pellet coating technology and micro-pellet production.

Technolog scaled pancreatin production to become a market leader.

Opened a state-of-the-art microbiological laboratory at Lekhim-Kharkiv.

Lekhim-Kharkiv significantly expanded its sterile product portfolio using a new high-performance ampoule filling line for small volume liquids.

Technolog commissioned an R&D laboratory and a specialized pilot workshop for investigational products.

Lekhim-Kharkiv commissioned a new quality control laboratory for physical and chemical testing.

Lekhim-Kharkiv expanded production capacity for aseptically prepared sterile products.

Lekhim-Kharkiv commissioned a new R&D laboratory for development of injectable solutions.

Lekhim-Kharkiv launched high-performance lines for suppositories and sachet-packaged powders for solution.

Technolog significantly expanded its portfolio and production capacity of solid dosage forms using new large-scale batch manufacturing technologies.

Lekhim invested $5 million USD in laboratory equipment and infrastructure for drug development and quality control across the Group.

Technolog expanded R&D and production scope to include disinfectants and dietary supplements.

Lekhim-Kharkiv expanded R&D and production scope to include medical devices.

Lekhim-Obukhiv commissioned a state-of-the-art laboratory for physical and chemical testing.

Technolog executed a comprehensive industrial upgrade, replacing critical equipment (rotary machines (tablet presses), packaging lines, tanks).

Lekhim-Kharkiv completed a significant technical upgrade of its aseptic filling lines to align with the latest regulatory requirements.

Lekhim-Obukhiv established a dedicated R&D Division, initiating the development of sterile pharmaceutical products.

Technolog commissioned a new state-of-the-art R&D Center (total area: 1,000 sq. m) to launch development of new medicinal products.

Lekhim executed a major $15 million USD investment initiative focused on the construction of new manufacturing units and the comprehensive technological re-equipping of production facilities across the Group.